Hemp THC Regulation: Federal Law, State Rules & Industry Impact

Executive Summary

A bipartisan congressional proposal introduced in July 2026 aims to establish federal regulation and taxation of hemp-derived THC products, potentially rescuing a multi-billion dollar industry from an imminent ban. The legislation arrives as the Drug Enforcement Administration's final rule reclassifying hemp-derived intoxicating cannabinoids approaches implementation, threatening to eliminate legal sales of delta-8 THC, delta-10 THC, THC-O, and similar products that have flourished in a regulatory gray zone since the 2018 Farm Bill legalized hemp. The proposal would create a federal framework distinguishing regulated hemp THC products from marijuana, impose excise taxes comparable to alcohol, and establish potency limits and testing requirements. With the hemp THC market estimated at $28 billion annually across gas stations, convenience stores, and online retailers, the stakes involve thousands of small businesses, state tax revenues, and consumer access in states without legal marijuana programs. The legislation faces uncertain prospects in a divided Congress, while the DEA ban remains scheduled absent congressional intervention.

Why This Matters

The regulatory fate of hemp THC products will determine whether a $28 billion industry continues operating or faces immediate shutdown, affecting retailers in all 50 states and millions of consumers. The hemp THC market emerged rapidly after the 2018 Farm Bill defined hemp as cannabis containing no more than 0.3 percent delta-9 THC on a dry weight basis. Manufacturers discovered they could synthesize intoxicating cannabinoids from CBD through chemical processes, creating products that technically complied with the hemp definition while producing psychoactive effects similar to marijuana. Delta-8 THC products alone generated an estimated $2 billion in sales in 2023, according to market research firm Brightfield Group. For consumers in states without legal marijuana programs, hemp THC products represent the only legal access to intoxicating cannabis. Approximately 60 million Americans live in states where marijuana remains fully prohibited, including Idaho, Kansas, Nebraska, and South Carolina. Veterans, elderly patients, and others seeking cannabis effects without participating in illicit markets have relied on hemp-derived products available at mainstream retailers. State governments have collected substantial tax revenues from hemp THC sales where state-level regulations exist. North Carolina imposed a 10 percent excise tax on hemp-derived consumable products in 2023, generating $14.7 million in the first year according to the state Department of Revenue. Minnesota's hemp THC regulations, which took effect in 2023, created a framework that other states have studied as a model. The business community affected extends beyond specialized hemp companies to include major convenience store chains, gas station operators, and e-commerce platforms. Circle K, 7-Eleven, and thousands of independent retailers added hemp THC products to their inventory between 2020 and 2025. The National Association of Convenience Stores estimated that 68 percent of convenience stores carried hemp-derived cannabinoid products as of early 2025. Opposition to unregulated hemp THC has united strange bedfellows: state-licensed marijuana operators who view hemp products as untaxed competition, public health advocates concerned about lack of testing and age verification, and law enforcement agencies reporting difficulties distinguishing legal hemp from illegal marijuana. The Cannabis Trade Federation, representing licensed marijuana businesses, has advocated for hemp THC regulation rather than prohibition, arguing that consumer demand will persist regardless of legal status.

Background and History

The hemp THC industry emerged from a legal loophole in the 2018 Farm Bill that defined hemp by delta-9 THC concentration alone, enabling synthesis of alternative intoxicating cannabinoids.

The 2018 Farm Bill and Hemp Legalization

The Agriculture Improvement Act of 2018, signed into law on December 20, 2018, removed hemp from Schedule I of the Controlled Substances Act. Section 10113 of the Farm Bill amended the definition of marijuana in 21 U.S.C. § 802(16) to exclude "hemp," defined as cannabis containing not more than 0.3 percent delta-9 tetrahydrocannabinol on a dry weight basis. The legislation, championed by Senate Majority Leader Mitch McConnell of Kentucky, aimed to support American farmers by legalizing industrial hemp cultivation for fiber, grain, and CBD extraction. The 0.3 percent threshold originated from a 1976 taxonomic paper by Canadian researchers Ernest Small and Arthur Cronquist, who proposed the arbitrary distinction to differentiate fiber cultivars from drug cultivars. Congress adopted this botanical classification without anticipating that manufacturers would exploit the specific reference to delta-9 THC while creating products containing other THC isomers. The Farm Bill explicitly preserved FDA authority over hemp-derived products intended for human consumption under 21 U.S.C. § 321. The legislation also maintained state authority to regulate hemp more restrictively than federal law, with Section 10114 allowing states to prohibit hemp cultivation and commerce within their borders.

Emergence of Delta-8 THC Products (2019-2021)

By late 2019, chemists discovered they could convert CBD isolate into delta-8 THC through chemical synthesis using acids and heat. Delta-8 THC, a naturally occurring cannabinoid present in cannabis at concentrations below 1 percent, produces intoxicating effects approximately 50-70 percent as potent as delta-9 THC according to anecdotal reports. The synthesized delta-8 technically qualified as hemp-derived since it originated from legal CBD extracted from compliant hemp plants. The first delta-8 THC products appeared in smoke shops and online retailers in early 2020. By summer 2021, delta-8 vape cartridges, gummies, and tinctures had become widely available. The COVID-19 pandemic accelerated online sales, with consumers ordering hemp THC products for delivery in states where marijuana remained illegal. 3Chi, founded by biochemist Gabriel Sciara, became one of the largest delta-8 brands, defending the products as legal hemp derivatives. The DEA issued an interim final rule on August 21, 2020, implementing the Farm Bill's hemp provisions. The rule stated that "all synthetically derived tetrahydrocannabinols remain schedule I controlled substances," creating immediate controversy about whether delta-8 THC qualified as synthetic. Industry advocates argued that conversion from naturally occurring CBD did not constitute synthesis, while the DEA maintained that chemical transformation created a synthetic controlled substance.

State Responses and Patchwork Regulation (2021-2024)

States responded inconsistently to hemp THC products. Alaska, Arizona, Arkansas, Colorado, Delaware, Idaho, Iowa, Montana, Nevada, New York, Rhode Island, Utah, Vermont, and Washington enacted prohibitions or restrictions on delta-8 THC and similar products between 2021 and 2023. These states typically amended their controlled substances laws to include "synthetically derived cannabinoids" or specified delta-8 THC by name. Other states moved toward regulation rather than prohibition. Louisiana enacted Act 164 in 2022, establishing a regulatory framework for hemp-derived consumable products with THC content limits and testing requirements. Minnesota passed legislation in 2022 creating a regulated market for hemp-derived edibles containing up to 5 milligrams of THC per serving and 50 milligrams per package. North Carolina followed in 2023 with House Bill 563, imposing a 10 percent excise tax and requiring lab testing. California presented a unique case. Despite having a mature legal marijuana market, California did not explicitly prohibit hemp THC products until Assembly Bill 1894 took effect on January 1, 2024. The legislation required hemp products containing detectable THC to be sold only through licensed cannabis retailers, effectively ending gas station and convenience store sales. The California Department of Cannabis Control estimated that unlicensed hemp THC sales had reached $1.5 billion annually in the state, representing significant tax revenue loss from the regulated marijuana market.

Proliferation of Novel Cannabinoids (2022-2024)

As states restricted delta-8 THC, manufacturers introduced additional hemp-derived intoxicating cannabinoids. Delta-10 THC, THC-O acetate, THC-P, and HHC (hexahydrocannabinol) appeared in products marketed as legal alternatives. Each compound claimed hemp origin through chemical conversion processes, maintaining the argument that products derived from compliant hemp remained legal under the Farm Bill. THC-O acetate, a synthetic analog created by acetylating THC, gained popularity in 2022 despite being clearly synthetic under any reasonable interpretation. The DEA issued a letter in February 2023 clarifying that THC-O did not occur naturally in cannabis and therefore constituted a controlled substance analog under 21 U.S.C. § 813. Most manufacturers discontinued THC-O products following the DEA statement, but the incident highlighted the industry's pattern of introducing novel compounds to circumvent restrictions. Public health concerns intensified as emergency room visits related to hemp THC products increased. The American Association of Poison Control Centers reported 2,362 exposure cases involving delta-8 THC in 2021, rising to 3,358 cases in 2022. Pediatric exposures, often involving children consuming gummies resembling candy, represented approximately 40 percent of cases. The lack of federal testing standards meant product potency and purity varied dramatically, with some products containing significantly higher THC levels than labeled.

The DEA's Reclassification Effort (2024-2026)

In May 2024, the DEA published a Notice of Proposed Rulemaking to reclassify marijuana from Schedule I to Schedule III of the Controlled Substances Act. The proposal, responding to a recommendation from the Department of Health and Human Services, would recognize marijuana's accepted medical use while maintaining federal prohibition for non-medical purposes. The NPRM included language clarifying that hemp-derived cannabinoids produced through chemical synthesis constitute controlled substances. The proposed rule stated that "tetrahydrocannabinols produced through chemical synthesis from non-cannabis materials, or through chemical modification of cannabinoids extracted from cannabis, do not meet the statutory definition of hemp and remain controlled substances." This language directly targeted the hemp THC industry's core legal argument. The DEA received over 43,000 public comments during the comment period, with hemp industry stakeholders submitting detailed objections. An administrative law judge conducted hearings on the proposed rule in late 2024 and early 2025. Hemp industry representatives argued that the Farm Bill's plain language legalized all hemp derivatives and that the DEA lacked authority to redefine hemp through rulemaking. The Cannabis Trade Federation, representing licensed marijuana businesses, supported the DEA's position that chemically converted cannabinoids should face the same regulatory requirements as marijuana. The DEA published its final rule on April 15, 2026, maintaining the language restricting chemically synthesized hemp-derived cannabinoids. The rule established a 180-day implementation period, meaning the ban would take effect on October 12, 2026, absent congressional intervention. The hemp industry immediately announced intentions to challenge the rule in federal court, with cases filed in the U.S. Court of Appeals for the Eighth Circuit and the D.C. Circuit.

Key Players

Drug Enforcement Administration

The DEA has maintained that chemically synthesized cannabinoids derived from hemp remain Schedule I controlled substances despite the 2018 Farm Bill. Administrator Anne Milgram, appointed in 2021, oversaw the agency's efforts to close the hemp THC loophole while simultaneously pursuing marijuana rescheduling. The DEA's Diversion Control Division, responsible for implementing the Controlled Substances Act, drafted the regulatory language addressing synthetic hemp cannabinoids. The agency has argued that allowing unregulated intoxicating products to proliferate contradicts congressional intent in legalizing industrial hemp for fiber and CBD production.

Food and Drug Administration

The FDA has maintained authority over hemp-derived products intended for human consumption but has declined to establish a comprehensive regulatory framework. The agency issued warning letters to specific companies making therapeutic claims about CBD products but has not systematically enforced against hemp THC products. FDA Commissioner Robert Califf testified before Congress in March 2025 that the agency lacked resources to regulate the hemp market without additional statutory authority and appropriations. The FDA's inaction created a regulatory vacuum that enabled the hemp THC market's explosive growth.

U.S. Hemp Roundtable

The U.S. Hemp Roundtable, a coalition of hemp businesses and advocates, has lobbied extensively to preserve hemp THC products' legal status. The organization argues that the 2018 Farm Bill legalized all hemp derivatives and that the DEA's interpretation exceeds statutory authority. Jonathan Miller, the Roundtable's general counsel and former Kentucky agriculture commissioner, has coordinated the industry's congressional outreach and legal strategy. The organization represents cultivators, processors, and retailers with combined annual revenues exceeding $10 billion.

Cannabis Trade Federation

The Cannabis Trade Federation, representing state-licensed marijuana operators, has advocated for regulating hemp THC products under frameworks similar to legal marijuana. The organization argues that unregulated hemp products undermine state marijuana programs by offering untaxed, untested alternatives. CEO Diane Czarkowski has testified that hemp THC regulation should include potency limits, testing requirements, and age restrictions comparable to alcohol. The Federation supported the DEA's reclassification rule while advocating for congressional action to establish clear regulatory authority.

National Association of Convenience Stores

NACS represents 150,000 convenience stores that became major hemp THC retailers between 2020 and 2025. The association has advocated for federal regulation rather than prohibition, arguing that eliminating hemp products would cost retailers $2.8 billion in annual sales. NACS has emphasized that convenience stores implement age verification procedures and support testing standards, positioning the industry as responsible stakeholders willing to comply with reasonable regulations.

State Regulators

State departments of agriculture and health have struggled with inconsistent federal guidance on hemp THC. The National Association of State Departments of Agriculture has called for clear federal standards to replace the current patchwork of state laws. North Carolina Agriculture Commissioner Steve Troxler, who implemented his state's hemp THC regulations, has advocated for a federal framework that preserves state flexibility while establishing baseline safety standards. California's Department of Cannabis Control has taken the opposite approach, requiring all THC products to flow through the licensed marijuana supply chain.

Legal and Regulatory Framework

The legal status of hemp THC products depends on interpreting the 2018 Farm Bill's hemp definition in conjunction with the Controlled Substances Act's provisions on synthetic substances. The Agriculture Improvement Act of 2018 amended 21 U.S.C. § 802(16) to exclude from the definition of marijuana "the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis." This language explicitly legalized hemp derivatives and cannabinoid isomers, which hemp industry advocates cite as authorizing delta-8 THC and similar compounds. However, 21 U.S.C. § 802(6) defines controlled substance analogs, and 21 U.S.C. § 813 grants the Attorney General authority to schedule substances substantially similar to controlled substances. The DEA has invoked these provisions to argue that chemically synthesized cannabinoids, even if derived from legal hemp, constitute controlled substance analogs when intended for human consumption. The Controlled Substances Act's definition of "synthetic" at 21 CFR § 1308.01 includes substances produced through chemical synthesis or chemical modification. The DEA's April 2026 final rule applied this definition to hemp-derived cannabinoids produced through isomerization, arguing that converting CBD to delta-8 THC through acid catalysis constitutes chemical modification creating a synthetic controlled substance. The Farm Bill preserved FDA authority under 21 U.S.C. § 321 to regulate hemp-derived products as food, dietary supplements, or drugs. Section 301(ll) of the Federal Food, Drug, and Cosmetic Act prohibits introducing into interstate commerce any food containing a drug ingredient, which the FDA has applied to CBD. However, the FDA has not invoked this authority systematically against hemp THC products, creating uncertainty about whether such products qualify as lawful food ingredients. State authority to regulate hemp more restrictively than federal law derives from the Farm Bill's Section 10114 and the Tenth Amendment's reservation of police powers to states. States that have prohibited hemp THC products typically amended their controlled substances schedules to include "synthetically derived tetrahydrocannabinols" or specified compounds like delta-8 THC. These state laws face legal challenges arguing that the Supremacy Clause preempts state restrictions on substances Congress legalized. The pending litigation challenging the DEA's final rule raises fundamental questions of administrative law and statutory interpretation. Hemp industry plaintiffs argue that the DEA exceeded its statutory authority by redefining hemp through rulemaking, violating the Administrative Procedure Act's prohibition on agency actions that are arbitrary, capricious, or contrary to law under 5 U.S.C. § 706. The cases will likely determine whether Chevron deference applies to the DEA's interpretation of the Farm Bill, or whether the major questions doctrine requires clear congressional authorization for regulatory actions with significant economic and political consequences.

The Congressional Proposal

The bipartisan legislation introduced on July 22, 2026, would establish federal regulation and taxation of hemp THC products while creating distinctions from marijuana based on potency and production methods. The Hemp Regulation and Taxation Act, introduced by Representative Earl Blumenauer of Oregon and Representative Nancy Mace of South Carolina, would amend the Internal Revenue Code to impose a federal excise tax on hemp-derived intoxicating products. The bill proposes a tax rate of $1.00 per milligram of total THC content, comparable to the taxation structure for alcohol on a per-dose basis. A 10-milligram edible would face a $10 federal excise tax, in addition to state and local taxes. The legislation would establish potency limits distinguishing regulated hemp products from marijuana. Products containing no more than 10 milligrams of total THC per serving and 100 milligrams per package would qualify for the hemp regulatory pathway. Products exceeding these limits would require licensing under state marijuana programs where legal, or would remain prohibited in states without legal marijuana frameworks. Testing and labeling requirements in the proposal mirror standards in mature marijuana markets. All hemp THC products would require third-party laboratory testing for potency, pesticides, heavy metals, and microbial contaminants. Labels would disclose total THC content, serving size, and health warnings. The bill would prohibit marketing to minors and require child-resistant packaging. The proposal would create a federal permitting system administered by the Alcohol and Tobacco Tax and Trade Bureau, which would transition to regulating hemp THC products alongside its existing alcohol and tobacco responsibilities. Manufacturers, distributors, and retailers would require federal permits, with application fees scaled to business size. The TTB would conduct inspections and enforce compliance with testing and labeling requirements. Critically, the legislation would supersede the DEA's final rule by explicitly authorizing hemp-derived cannabinoids produced through chemical conversion from CBD, provided the source material originated from compliant hemp plants. The bill would amend 21 U.S.C. § 802(16) to clarify that "derivatives" includes cannabinoids produced through isomerization and other chemical processes, resolving the statutory ambiguity the DEA exploited. The proposal includes revenue-sharing provisions directing 50 percent of federal excise tax collections to states based on where products are sold. States would receive quarterly payments to support regulation, enforcement, and substance abuse prevention programs. The Congressional Budget Office has not yet scored the legislation, but sponsors estimate it could generate $2.8 billion in annual federal revenue based on current market size.

State-by-State Breakdown

States have adopted dramatically different approaches to hemp THC products, creating a complex patchwork of prohibition, regulation, and unregulated markets.

Alabama

Alabama has not enacted specific restrictions on hemp-derived THC products. The Alabama Department of Agriculture and Industries regulates hemp cultivation under the 2018 Farm Bill but has not addressed intoxicating hemp products. Delta-8 THC and similar products remain widely available in convenience stores and smoke shops. The state's medical marijuana program, authorized in 2021, has not yet begun operations, leaving hemp products as the only legal cannabis option.

Alaska

Alaska prohibited delta-8 THC and other hemp-derived intoxicating cannabinoids in 2021 by adding them to the state's Schedule VIA controlled substances. The Alaska Marijuana Control Board determined that intoxicating hemp products competed unfairly with the state's licensed marijuana market, which has operated since 2016. Possession limits and regulations for marijuana apply, with adults 21 and older permitted to possess up to one ounce.

Arizona

Arizona amended its controlled substances law in 2021 to prohibit delta-8 THC and "any artificially derived cannabinoid." The Arizona Department of Health Services determined that chemically converted hemp cannabinoids did not qualify as naturally occurring hemp derivatives. The state's adult-use marijuana program, which launched in 2021, allows adults 21 and older to possess up to one ounce and cultivate up to six plants for personal use.

Arkansas

Arkansas banned delta-8 THC and similar products in 2021 through an emergency rule by the Alcoholic Beverage Control Division. The state subsequently codified the prohibition in Act 629 of 2021, which added "synthetically derived tetrahydrocannabinols" to Schedule VI. Arkansas operates a medical marijuana program established by constitutional amendment in 2016, serving approximately 80,000 registered patients.

California

California enacted Assembly Bill 1894 in 2023, requiring all hemp products containing detectable THC to be sold exclusively through licensed cannabis retailers. The law took effect January 1, 2024, eliminating the previously unregulated hemp THC market in convenience stores and online. The California Department of Cannabis Control estimated the law would redirect $1.5 billion in annual sales into the regulated market, generating approximately $225 million in additional tax revenue. Adults 21 and older may purchase up to one ounce of cannabis from licensed retailers.

Colorado

Colorado restricted hemp-derived THC products through regulations adopted by the Colorado Department of Public Health and Environment in 2022. The state requires hemp products containing more than 0.3 percent total THC to be sold through licensed marijuana retailers. Products containing 0.3 percent or less total THC may be sold in general retail but face serving size limits of 2 milligrams per serving. Colorado's marijuana program, the first in the nation, has operated since 2014.

Florida

Florida has not enacted statewide restrictions on hemp THC products, creating one of the largest unregulated markets. Delta-8 THC and similar products are widely available in gas stations, convenience stores, and dedicated hemp shops. The Florida Department of Agriculture and Consumer Services regulates hemp cultivation but has not addressed intoxicating products. Several local jurisdictions, including Sarasota County, have enacted local bans. Florida operates a medical marijuana program serving over 800,000 registered patients, but adult-use marijuana remains illegal.

Georgia

Georgia permits hemp THC products without specific state-level regulations beyond general hemp cultivation rules. The Georgia Department of Agriculture oversees hemp farming but has not established testing or labeling requirements for hemp-derived intoxicating products. The state's limited medical marijuana program, established in 2019, allows low-THC cannabis oil for specific medical conditions but has faced implementation challenges.

Idaho

Idaho maintains one of the strictest cannabis policies in the nation, prohibiting all THC products including hemp-derived cannabinoids. Idaho Code § 37-2701 defines marijuana to include all tetrahydrocannabinols regardless of source. The state has not established a hemp program under the 2018 Farm Bill, instead maintaining a prohibition on all cannabis cultivation and products. CBD products must contain zero THC to be legal in Idaho.

Illinois

Illinois has not restricted hemp-derived THC products at the state level, despite operating a mature adult-use marijuana market since 2020. The Illinois Department of Agriculture regulates hemp cultivation but has not addressed intoxicating hemp products. Industry observers note that hemp THC products compete with licensed marijuana sales, which generated $1.9 billion in revenue in 2023. Adults 21 and older may purchase up to 30 grams of cannabis flower from licensed dispensaries.

Kansas

Kansas permits hemp cultivation and CBD products but has not specifically addressed delta-8 THC and similar intoxicating hemp cannabinoids. The Kansas Department of Agriculture regulates hemp under the 2018 Farm Bill. Hemp THC products are available in convenience stores and smoke shops, representing the only legal intoxicating cannabis option in a state where marijuana remains fully prohibited.

Louisiana

Louisiana enacted Act 164 in 2022, creating a regulatory framework for hemp-derived consumable products. The law limits hemp edibles to 8 milligrams of total THC per serving and requires third-party lab testing. The Louisiana Department of Agriculture and Forestry oversees compliance. The state also operates a medical marijuana program, creating parallel regulated markets for hemp and marijuana products.

Massachusetts

Massachusetts requires hemp products containing intoxicating levels of THC to be sold through licensed cannabis retailers under regulations adopted by the Cannabis Control Commission in 2023. The state's adult-use marijuana program, operational since 2018, generated $1.6 billion in sales in 2023. Adults 21 and older may purchase up to one ounce from licensed retailers or cultivate up to six plants at home.

Michigan

Michigan has not enacted specific restrictions on hemp-derived THC products, despite operating adult-use marijuana sales since 2019. The Michigan Department of Agriculture and Rural Development regulates hemp cultivation. Hemp THC products compete with the licensed marijuana market, which generated $3.0 billion in sales in 2023, the third-largest state market nationally. Adults 21 and older may possess up to 2.5 ounces and cultivate up to 12 plants.

Minnesota

Minnesota established a regulated hemp THC market through legislation enacted in 2022. The law permits hemp-derived edibles containing up to 5 milligrams of THC per serving and 50 milligrams per package. Products must be manufactured in licensed facilities and undergo testing. The Minnesota Department of Agriculture oversees the program. The state subsequently legalized adult-use marijuana in 2023, creating parallel regulatory pathways.

Mississippi

Mississippi permits hemp cultivation and has not specifically restricted delta-8 THC or similar products. The Mississippi Department of Agriculture and Commerce regulates hemp farming under the 2018 Farm Bill. The state operates a medical marijuana program established by voter initiative in 2020 and implemented through legislation in 2022, but adult-use marijuana remains prohibited.

Montana

Montana banned delta-8 THC and synthetically derived cannabinoids in 2021 through amendments to the state's controlled substances schedule. The Montana Department of Public Health and Human Services determined that chemically converted hemp products did not qualify as natural hemp derivatives. The state's adult-use marijuana program, approved by voters in 2020, began sales in 2022. Adults 21 and older may possess up to one ounce.

Nevada

Nevada prohibited hemp-derived intoxicating products in 2021, requiring all THC products to be sold through licensed cannabis dispensaries. The Nevada Cannabis Compliance Board determined that delta-8 THC and similar products competed with the regulated marijuana market. Nevada's adult-use program, operational since 2017, generated $1.2 billion in sales in 2023. Adults 21 and older may purchase up to one ounce from licensed retailers.

New York

New York initially allowed hemp THC products but reversed course with regulations adopted by the Office of Cannabis Management in 2023. The state now requires all intoxicating cannabis products, including hemp-derived items, to be sold through licensed cannabis retailers. The policy aims to protect the state's developing adult-use marijuana market, which began licensed sales in 2022. Adults 21 and older may possess up to three ounces.

North Carolina

North Carolina enacted House Bill 563 in 2023, establishing comprehensive hemp THC regulations. The law imposes a 10 percent excise tax on hemp-derived consumable products and requires lab testing for potency and contaminants. Products are limited to 10 milligrams of total THC per serving. The North Carolina Department of Agriculture and Consumer Services administers the program, which generated $14.7 million in tax revenue in its first year. Marijuana remains illegal in North Carolina.

Ohio

Ohio has not restricted hemp-derived THC products at the state level. The Ohio Department of Agriculture regulates hemp cultivation but has not addressed intoxicating products. Hemp THC items are widely available in convenience stores and smoke shops. Ohio voters approved adult-use marijuana legalization in November 2023, with licensed sales beginning in 2024. The hemp market provided legal intoxicating cannabis access during the implementation period.

Oklahoma

Oklahoma permits hemp THC products without specific state regulations beyond hemp cultivation rules. The Oklahoma Department of Agriculture, Food and Forestry oversees hemp farming. The state operates one of the nation's largest medical marijuana programs, with over 400,000 registered patients and more than 2,000 dispensaries, but has not extended regulations to hemp-derived products.

Oregon

Oregon requires hemp products containing intoxicating levels of cannabinoids to be sold through licensed cannabis retailers under rules adopted by the Oregon Liquor and Cannabis Commission. The state's adult-use marijuana program, operational since 2015, faces significant competition from illicit markets. Adults 21 and older may purchase up to one ounce from licensed retailers or cultivate up to four plants at home.

Rhode Island

Rhode Island banned delta-8 THC and synthetically derived cannabinoids in 2021 through amendments to the state's controlled substances law. The Rhode Island Department of Health determined that chemically converted hemp products should be regulated as marijuana. The state's adult-use marijuana program began licensed sales in 2022. Adults 21 and older may possess up to one ounce.

South Carolina

South Carolina permits hemp cultivation and CBD products but has not specifically addressed delta-8 THC and similar intoxicating cannabinoids. The South Carolina Department of Agriculture regulates hemp farming. Hemp THC products are available in convenience stores and smoke shops, representing the only legal intoxicating cannabis option in a state where marijuana remains fully prohibited.

Tennessee

Tennessee initially allowed hemp THC products but enacted restrictions in 2023 through amendments to the state's food and drug laws. Products containing more than 0.3 percent total THC are prohibited from general retail sale. The Tennessee Department of Agriculture oversees hemp cultivation. Medical marijuana remains illegal in Tennessee, making the hemp market particularly significant for consumers seeking cannabis products.

Texas

Texas permits hemp cultivation and has not enacted statewide restrictions on delta-8 THC or similar products, creating one of the nation's largest hemp THC markets. The Texas Department of State Health Services regulates hemp under the 2018 Farm Bill. Several local jurisdictions have attempted bans, but state law preempts local hemp regulations. The state operates a limited medical marijuana program for specific conditions, but adult-use marijuana remains illegal.

Utah

Utah banned delta-8 THC and synthetically derived cannabinoids in 2021 through amendments to the state's controlled substances schedule. The Utah Department of Agriculture and Food determined that chemically converted hemp products did not qualify as legal hemp derivatives. Utah operates a medical marijuana program established in 2018, serving approximately 35,000 registered patients.

Vermont

Vermont restricted hemp-derived intoxicating products in 2022, requiring products containing more than 0.3 percent total THC to be sold through licensed cannabis retailers. The Vermont Agency of Agriculture, Food and Markets oversees hemp cultivation, while the Cannabis Control Board regulates marijuana. The state's adult-use program began licensed sales in 2022. Adults 21 and older may possess up to one ounce or cultivate up to two mature plants.

Virginia

Virginia permits hemp THC products without specific state-level restrictions beyond general hemp regulations. The Virginia Department of Agriculture and Consumer Services oversees hemp cultivation. The state legalized adult-use marijuana possession in 2021 but has not yet established a licensed retail market, leaving hemp products as the primary legal purchase option. Adults 21 and older may possess up to one ounce and cultivate up to four plants at home.

Washington

Washington prohibited delta-8 THC and synthetically derived cannabinoids in 2022 through regulations adopted by the Washington State Liquor and Cannabis Board. The state determined that chemically converted hemp products competed unfairly with the licensed marijuana market. Washington's adult-use program, operational since 2014, generated $1.4 billion in sales in 2023. Adults 21 and older may purchase up to one ounce from licensed retailers.

Market and Business Implications

The hemp THC industry's regulatory fate will determine whether $28 billion in annual commerce continues or shifts to licensed marijuana markets and illicit channels. Multi-state operators in the licensed marijuana industry view hemp THC regulation as essential to competitive fairness. Curaleaf, Trulieve, Green Thumb Industries, and other MSOs have invested billions in state-licensed infrastructure subject to strict testing, taxation, and compliance requirements. Unregulated hemp products sold at convenience stores undercut licensed marijuana pricing while avoiding the regulatory costs that burden MSOs. Curaleaf CEO Matt Darin stated in a February 2025 earnings call that hemp competition had reduced the company's revenue by an estimated 8-12 percent in